Back to School: How biopharma can reboot drug development. Access exclusive analysis here

One-two punch against cholesterol

With Phase II data in hand for its A-002 secretory phospholipase A2 inhibitor, Anthera Pharmaceuticals Inc. is setting its sights on supplanting a blockbuster drug - Zetia ezetimibe - as the first choice for add-on therapy to statins. The key, according to Anthera, is that A-002 works through at

Read the full 498 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE